AKT1 and meningioma: Thus, vismodegib or sonidegib are currently tested in combination with either the focal adhesion kinase inhibitor GSK2256098, the AKT-inhibitor capivasertib or the CDK4/6-inhibitor abemaciclib in the treatment of meningioma (NCT02523014).